Poliovirus Vaccine . | Seroprevalence, % (No. Seropositive/Total No.) . | . | . | . | . |
---|---|---|---|---|---|
. | 14 weeks (n = 250) . | 18 weeks (n = 224) . | 9 months (n = 250) . | 10 months (n = 462) . | 21 months (n = 445) . |
Poliovirus type 1 | |||||
Arm A (2 IPV) | 94 (117/125) | 98 (106/108) | … | 100 (108/108) | 100 (104/104) |
Arm B (2 fIPV) | 96 (120/125) | 97 (113/116) | … | 100 (114/114) | 100 (111/111) |
Arm C (2 IPV) | … | … | 100 (125/125) | 100 (122/122) | 100 (117/117) |
Arm D (1 IPV + 1fIPV) | … | … | 99 (124/125) | 100 (118/118) | 100 (113/113) |
Poliovirus type 3 | … | … | … | … | … |
Arm A (2 IPV) | 88 (110/125) | 95 (103/108) | … | 100 (108/108) | 100 (104/104) |
Arm B (2 fIPV) | 86 (108/125) | 94 (109/116) | … | 98 (112/114) | 99 (110/111) |
Arm C (2 IPV) | … | … | 95 (119/125) | 100 (122/122) | 100 (117/117) |
Arm D (1 IPV + 1fIPV) | … | … | 99 (124/125) | 100 (118/118) | 100 (113/113) |
Poliovirus Vaccine . | Seroprevalence, % (No. Seropositive/Total No.) . | . | . | . | . |
---|---|---|---|---|---|
. | 14 weeks (n = 250) . | 18 weeks (n = 224) . | 9 months (n = 250) . | 10 months (n = 462) . | 21 months (n = 445) . |
Poliovirus type 1 | |||||
Arm A (2 IPV) | 94 (117/125) | 98 (106/108) | … | 100 (108/108) | 100 (104/104) |
Arm B (2 fIPV) | 96 (120/125) | 97 (113/116) | … | 100 (114/114) | 100 (111/111) |
Arm C (2 IPV) | … | … | 100 (125/125) | 100 (122/122) | 100 (117/117) |
Arm D (1 IPV + 1fIPV) | … | … | 99 (124/125) | 100 (118/118) | 100 (113/113) |
Poliovirus type 3 | … | … | … | … | … |
Arm A (2 IPV) | 88 (110/125) | 95 (103/108) | … | 100 (108/108) | 100 (104/104) |
Arm B (2 fIPV) | 86 (108/125) | 94 (109/116) | … | 98 (112/114) | 99 (110/111) |
Arm C (2 IPV) | … | … | 95 (119/125) | 100 (122/122) | 100 (117/117) |
Arm D (1 IPV + 1fIPV) | … | … | 99 (124/125) | 100 (118/118) | 100 (113/113) |
Abbreviation: fIPV, fractional inactivated poliovirus vaccine.
Poliovirus Vaccine . | Seroprevalence, % (No. Seropositive/Total No.) . | . | . | . | . |
---|---|---|---|---|---|
. | 14 weeks (n = 250) . | 18 weeks (n = 224) . | 9 months (n = 250) . | 10 months (n = 462) . | 21 months (n = 445) . |
Poliovirus type 1 | |||||
Arm A (2 IPV) | 94 (117/125) | 98 (106/108) | … | 100 (108/108) | 100 (104/104) |
Arm B (2 fIPV) | 96 (120/125) | 97 (113/116) | … | 100 (114/114) | 100 (111/111) |
Arm C (2 IPV) | … | … | 100 (125/125) | 100 (122/122) | 100 (117/117) |
Arm D (1 IPV + 1fIPV) | … | … | 99 (124/125) | 100 (118/118) | 100 (113/113) |
Poliovirus type 3 | … | … | … | … | … |
Arm A (2 IPV) | 88 (110/125) | 95 (103/108) | … | 100 (108/108) | 100 (104/104) |
Arm B (2 fIPV) | 86 (108/125) | 94 (109/116) | … | 98 (112/114) | 99 (110/111) |
Arm C (2 IPV) | … | … | 95 (119/125) | 100 (122/122) | 100 (117/117) |
Arm D (1 IPV + 1fIPV) | … | … | 99 (124/125) | 100 (118/118) | 100 (113/113) |
Poliovirus Vaccine . | Seroprevalence, % (No. Seropositive/Total No.) . | . | . | . | . |
---|---|---|---|---|---|
. | 14 weeks (n = 250) . | 18 weeks (n = 224) . | 9 months (n = 250) . | 10 months (n = 462) . | 21 months (n = 445) . |
Poliovirus type 1 | |||||
Arm A (2 IPV) | 94 (117/125) | 98 (106/108) | … | 100 (108/108) | 100 (104/104) |
Arm B (2 fIPV) | 96 (120/125) | 97 (113/116) | … | 100 (114/114) | 100 (111/111) |
Arm C (2 IPV) | … | … | 100 (125/125) | 100 (122/122) | 100 (117/117) |
Arm D (1 IPV + 1fIPV) | … | … | 99 (124/125) | 100 (118/118) | 100 (113/113) |
Poliovirus type 3 | … | … | … | … | … |
Arm A (2 IPV) | 88 (110/125) | 95 (103/108) | … | 100 (108/108) | 100 (104/104) |
Arm B (2 fIPV) | 86 (108/125) | 94 (109/116) | … | 98 (112/114) | 99 (110/111) |
Arm C (2 IPV) | … | … | 95 (119/125) | 100 (122/122) | 100 (117/117) |
Arm D (1 IPV + 1fIPV) | … | … | 99 (124/125) | 100 (118/118) | 100 (113/113) |
Abbreviation: fIPV, fractional inactivated poliovirus vaccine.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.